Clariant

Photo

Clariant Opens Catalyst R&D Center in China

Clariant Catalysts has opened a new R&D center at its One Clariant Campus (OCC) in Shanghai. The research unit is part of the Swiss specialty chemicals producer’s new Innovation Center China in the east coast metropolis. The company counts itself among a handful of international players to have built a full-fledged comprehensive catalyst research unit in China.

Photo

CO2-Neutral Chemical Industry

The European Chemical Industry has set out on an ambitious path to become carbon neutral. Germany, as one of the major chemical manufacturing nations, has committed to achieve this goal by 2050.

Photo

Clariant and India Glycols Form Renewables JV

Clariant and India Glycols Limited (IGL) are forming a joint venture for renewable ethylene oxide (EO) derivatives. To support production, IGL has entered into long-term supply agreement for EO made from bio-ethanol as well as further utilities.

Photo

Clariant Finances Catalyst Research at ETH Zurich

Clariant has signed a cooperation agreement with the Swiss Federal Institute of Technology (ETH Zurich) to support research in catalysis and sustainable chemistry. It is providing the university with what it says is “a significant financial contribution” over an initial period of ten years. Terms were not disclosed.

Photo

Conrad Keijzer Named new Clariant CEO

The board of directors at Swiss specialty chemicals producer Clariant has tapped Conrad Keijzer to be the company’s new CEO. The 52-year-old Dutch citizen will take up the job on Jan. 1, 2021, and interim CEO Harriolf Kottmann will again focus on his duties as chairman of the board.

Photo

Clariant to Restructure and Cut Jobs

After downsizing operations through divestments over the past year, Swiss specialty chemicals producer Clariant now plans to restructure its corporate organization to reflect the present leaner status and shift the emphasis of its portfolio to higher value-added products.

Photo

Clariant and Chemtex in Sunliquid Pact

Swiss specialty chemicals company Clariant has formed a strategic partnership with engineering group Chemtex to market its sunliquid technology as well as services and supplies for advanced biofuel plants in China.

Photo

Clariant Inks Fourth Sunliquid License

Clariant has signed a licensing deal for its sunliquid cellulosic ethanol technology with Bulgaria’s Eta Bio. The Swiss specialty chemicals group said the agreement, the fourth for sunliquid, represents another significant step toward the technology’s commercialization and also gives it a foothold in the agricultural sector.

Photo

EU Fines Clariant for Ethylene Price Fixing

The European Commission has fined Swiss specialty chemicals producer Clariant €155.8 million for its role in an ethylene purchasing scheme that also implicated other chemical producers, including US-based Celanese.

Photo

Clariant and Ineratec in Gas-to-Liquids Pact

Clariant is collaborating with Ineratec, a spin-off from the Karlsruhe Institute of Technology (KIT), to develop and commercialize novel technologies for producing renewable fuels and chemicals.

Photo

TechnipFMC Joins Clariant on ACN Catalyst

Major construction and engineering group TechnipFMC has entered into a joint development agreement with Clariant Catalysts to commercialize the Swiss company’s new AcryloMax propylene ammoxidation catalyst to produce fiber intermediate acrylonitrile (ACN).

Photo

Circular Economy

The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.

Photo

Innovative Chemistry Between Mountains and Lakes

Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.

203 more articles

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.